Navigation Links
Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Date:7/19/2012

SAN DIEGO and EDMONTON, Alberta, July 19, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.  The objective of the trial is to determine safety, achievement and maintenance of insulin independence and to obtain preliminary data on the efficacy of emricasan to maintain adequate immunological protection against both allo- and autoimmunity of islet cell transplant recipients.  The sponsor of the trial is the University of Alberta and the principal investigator is A. M. James Shapiro, M.D., Ph.D.

"Preclinical studies support the use of a pan-caspase inhibitor therapy to broaden the availability of clinical islet transplantation.  Enhancing islet engraftment post-transplant should prolong graft longevity, resulting in a more quiescent immunological state and thereby enhancing long-term rates of insulin independence.  Inhibition of islet apoptosis in the immediate post-transplant period may reduce the amount and intensity of anti-rejection therapy, accelerating 'accommodation' and drug minimization.  If this could be achieved, or if stable immunological tolerance was enhanced through emricasan treatment, islet transplantation would be potentially safer and therefore more available to a broader spectrum of patients with type 1 diabetes," said Dr. Shapiro.  "Over 750 islet transplantations are now carried out each year in 30 active centers worldwide.  Diabetologists, funding organizations and regulatory agencies recognize islet transplantation as an effective therapy to prevent episodic hypoglycemia, correct glycated hemoglobin and reduce risk of secondary diabetic complication."

"As Conatus pursues the development of emricasan on our own in liver disease, I am pleased to support new treatment paradigms in diabetes.  If the results in humans are similar to the preclinical data, many more patients will benefit from islet cell transplantation," said Steven J. Mento, President and Chief Executive Officer of Conatus Pharmaceuticals.

The trial will be conducted in two sequential pilot study groups of six patients each with two different dosages of emricasan for 14 days.  Once optimal dosing has been determined from these pilot studies, the next proposed study would be a randomized, placebo-controlled study to explore the safety and efficacy of emricasan combined with other islet transplant treatment medications.

Emricasan is a novel small molecule inhibitor of activated caspases. Caspases are enzymes responsible for executing apoptotic pathways, or programmed cell death and are also involved in processing cytokines involved in inflammation. Conatus is planning Phase 3 clinical trials early next year to test emricasan as a treatment in patients for acute liver failure with underlying cirrhosis, and in patients with liver fibrosis. Emricasan has shown specificity in assays measuring caspase inhibition, and reduced apoptosis in a variety of cellular assays. It also demonstrated efficacy in a number of preclinical models of liver disease and islet transplantation as well as in models of damage to other organ systems. Positive Phase 2 data in a 12-week study in patients with chronic Hepatitis C virus (HCV) infection have indicated that the oral formulation of emricasan was well tolerated, and significantly improved key markers of liver damage as early as 7 days after initiation of therapy.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development primarily as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.  Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
2. Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
3. Global Angiogenesis Inhibitors and Stimulators Industry
4. Global Markets for Enzyme Inhibitors
5. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
6. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
9. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
10. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
11. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. To ... $835 million in resolved debt for its clients. , Credit card debt, unpaid hospital ... of debt settled by the company. With more than a decade of combined service ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... winners of the Entrepreneur Innovation Awards (EIA), held this past Thursday night at ... Connecticut-based companies and entrepreneurs, presented their innovative project ideas to a panel of ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” with an educational ... as it focused on best practices for third party administrators (TPAs) related to ...
(Date:9/19/2017)... ... ... The Semper Fi Fund, one of the nation’s highest-rated veteran nonprofits serving ... and a compelling documentary that provide unique insights and powerful advice to help address ... ongoing mission. , Each of the videos focuses on a specific issue that’s highly ...
(Date:9/19/2017)... Toronto, Ontario (PRWEB) , ... September 19, 2017 , ... ... governmental regulation of pollutants have fallen on deaf ears, leaving the water industry itself ... one company that stays ahead of the curve in the field of natural ...
Breaking Medicine News(10 mins):